Presentation on Tuesday December 15that 11:00am EST LOS ANGELES, CA - (NewMediaWire) - December 08, 2020 - Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announcedthat it will… Read More..

PRINCETON, N.J., Dec. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has demonstrated extended protection with its heat stable ricin toxin… Read More..

- SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term Milestones, plus Tiered Royalties - - 3D Medicines to Lead Clinical Development and Commercialization of GPS and GPS+ in Greater China - - SELLAS Retains Rights in the Rest of… Read More..